



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01) A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2022/034660

(22) International Filing Date:

23 June 2022 (23.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/214,765	24 June 2021 (24.06.2021)	US
63/236,635	24 August 2021 (24.08.2021)	US
63/277,547	09 November 2021 (09.11.2021)	US
63/279,877	16 November 2021 (16.11.2021)	US
63/321,605	18 March 2022 (18.03.2022)	US


(71) Applicant: **ERASCA, INC.** [US/US]; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US).(72) Inventors: **SHOEMAKER, Robert Field**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US).

LEW, Erin Denise; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US). **LIN, Wei**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US). **BRILL, Leslie Harris**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US). **MARTIN, Leenus**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US). **ZHANG, Jingchuan**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US). **OH, Joanne**; 3115 Merryfield Row, Suite 300, San Diego, California 92121 (US).

(74) Agent: **BONNEFOUS, Celine M.**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: ERK1/2 AND EGFR INHIBITORS COMBINATION THERAPY



(57) Abstract: The present disclosure relates generally to the use of an ERK1/2 inhibitor in combination with a EGFR inhibitor for treating cancer, specifically solid tumors. The present disclosure also relates to the use of an ERK1/2 inhibitor in combination with a EGFR inhibitor and a BRAF inhibitor for treating cancer, specifically solid tumors.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*